查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970242

全球新型抗病毒藥物市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Novel Antiviral Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 164 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計到 2034 年，新型抗病毒藥物的市場規模將從 2025 年的 783.6 億美元達到 969.2 億美元，並預計從 2026 年到 2034 年將以 2.39% 的複合年成長率成長。

新型抗病毒藥物市場正進入關鍵的擴張階段，其驅動力包括新興感染疾病、病毒變異以及分子藥理學的進步。未來藥物研發預計將依賴高通量篩檢、人工智慧驅動的分子建模和基於結構的藥物設計，以識別病毒複製和免疫逃脫的有效抑制劑。包括奈米顆粒載體和標靶生技藥品在內的新一代遞送系統，將在最大限度降低全身毒性的同時，最佳化治療效果。

精準醫療方法將基於病毒基因型和宿主免疫特徵，進一步實現抗病毒療法的個人化，從而為每位患者量身定做治療方案。整合人工智慧驅動的臨床試驗模擬、預測性藥物動力學和In Silico毒性評估，將縮短研發週期，並加速產品上市速度。針對多種病毒通路聯合治療也將成為標準療法，旨在預防抗藥性並改善患者預後。

生產流程的永續性和擴充性，以及全球監管的協調統一，將有助於在疫情爆發和大流行期間快速部署。未來的抗病毒藥物市場將由創新藥物模式、適應性臨床通訊協定以及生物製藥開發公司、研究機構和數位健康平台之間的策略合作所定義，新型抗病毒藥物將成為感染疾病預防和控制的關鍵工具。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：新型抗病毒藥物的全球市場：按類型分類

  • 市場分析、洞察與預測
  • 按品牌
  • 學名藥

第5章：新型抗病毒藥物的全球市場：按藥物類別分類

  • 市場分析、洞察與預測
  • DNA聚合酵素抑制劑
  • 逆轉錄酶抑制劑
  • 蛋白酶抑制劑
  • 神經氨酸酶抑制劑
  • 其他

第6章：新型抗病毒藥物的全球市場：按分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第7章 新型抗病毒藥物全球市場：依應用領域分類

  • 市場分析、洞察與預測
  • HIV
  • 肝炎
  • 皰疹
  • 流感
  • 其他

第8章：全球新型抗病毒藥物市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • F. Hoffmann-La Roche Ltd
    • GSK Plc
    • AbbVie Inc
    • Merck & Co. Inc
    • Johnson & Johnson Services Inc
    • Bristol-Myers Squibb Company
    • Cipla Inc
    • Aurobindo Pharma
    • Sun Pharmaceutical Industries
    • Dr. Reddy'S Laboratories Ltd
簡介目錄
Product Code: VMR11214755

The Novel Antiviral Drugs Market size is expected to reach USD 96.92 Billion in 2034 from USD 78.36 Billion (2025) growing at a CAGR of 2.39% during 2026-2034.

The novel antiviral drugs market is entering a pivotal expansion phase driven by emerging infectious diseases, viral mutations, and advances in molecular pharmacology. Future drug development will rely on high-throughput screening, AI-guided molecular modeling, and structure-based design to identify potent inhibitors of viral replication and immune evasion. Next-generation delivery systems-including nanoparticle carriers and targeted biologics-will optimize therapeutic efficacy while minimizing systemic toxicity.

Precision medicine approaches will further tailor antiviral therapies based on viral genotyping and host immune profiles, enabling individualized treatment regimens. Integrating AI-driven clinical trial simulations, predictive pharmacokinetics, and in silico toxicity assessments will reduce development timelines and accelerate market readiness. Combination therapies targeting multiple viral pathways will also emerge as standard practice to prevent resistance development and improve patient outcomes.

Sustainability and scalability in manufacturing processes, coupled with global regulatory harmonization, will facilitate rapid deployment during epidemic or pandemic scenarios. Future antiviral markets will be defined by innovative drug modalities, adaptive clinical protocols, and strategic collaborations between biopharmaceutical developers, research institutions, and digital health platforms-positioning novel antivirals as critical tools in proactive infectious disease management.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type Scope

  • Branded
  • Generics

By Drug Class Scope

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Distribution Channel Scope

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Application Scope

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, GSK plc, AbbVie Inc, Merck Co Inc, Johnson Johnson Services Inc, BristolMyers Squibb Company, Cipla Inc, Aurobindo Pharma, Sun Pharmaceutical Industries, Dr Reddys Laboratories Ltd
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY TYPE SCOPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Type Scope
  • 4.2. Branded Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Generics Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DRUG CLASS SCOPE 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class Scope
  • 5.2. DNA Polymerase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Reverse Transcriptase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Protease Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Neuraminidase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY DISTRIBUTION CHANNEL SCOPE 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel Scope
  • 6.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY APPLICATION SCOPE 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Application Scope
  • 7.2. HIV Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Hepatitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Herpes Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.5. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL NOVEL ANTIVIRAL DRUGS MARKET: BY REGION 2022-2034(USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Type Scope
    • 8.2.2 By Drug Class Scope
    • 8.2.3 By Distribution Channel Scope
    • 8.2.4 By Application Scope
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Type Scope
    • 8.3.2 By Drug Class Scope
    • 8.3.3 By Distribution Channel Scope
    • 8.3.4 By Application Scope
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Type Scope
    • 8.4.2 By Drug Class Scope
    • 8.4.3 By Distribution Channel Scope
    • 8.4.4 By Application Scope
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Type Scope
    • 8.5.2 By Drug Class Scope
    • 8.5.3 By Distribution Channel Scope
    • 8.5.4 By Application Scope
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 South East Asia
    • 8.5.10 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Type Scope
    • 8.6.2 By Drug Class Scope
    • 8.6.3 By Distribution Channel Scope
    • 8.6.4 By Application Scope
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL NOVEL ANTIVIRAL DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 F. Hoffmann-La Roche Ltd
    • 10.2.2 GSK Plc
    • 10.2.3 AbbVie Inc
    • 10.2.4 Merck & Co. Inc
    • 10.2.5 Johnson & Johnson Services Inc
    • 10.2.6 Bristol-Myers Squibb Company
    • 10.2.7 Cipla Inc
    • 10.2.8 Aurobindo Pharma
    • 10.2.9 Sun Pharmaceutical Industries
    • 10.2.10 Dr. Reddy'S Laboratories Ltd